Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CheckMate 744 in relapsed/refractory CD30-positive classic Hodgkin lymphoma
2016-002347-41Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab, brentuximab vedotin and bendamustine in classical Hodgkin lymphoma (cHL) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Event-free survival. Started Jan 2017; status: completed.
02
Drugs
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on 2016-002347-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002347-41.